Zoetis (ZTS) Stock Price, News & Analysis

Company Overview

Zoetis Inc. (NYSE: ZTS) is a global animal health company dedicated to discovering, developing, manufacturing and commercializing a broad portfolio of veterinary medicines, vaccines and diagnostic products. Created as a spin-off from Pfizer in 2013, Zoetis has built a leadership position in animal health by focusing on science-based research and innovation. Its product range addresses the needs of both livestock producers—covering cattle, swine, poultry and aquaculture—and companion animal owners, with solutions for dogs, cats and horses.

The company’s offerings include anti-infective, anti-inflammatory and pain management therapies as well as parasiticides, vaccines and reproductive health products for farm and ranch animals. For companion animals, Zoetis provides prescription treatments for conditions such as arthritis, cancer and dermatology, alongside routine vaccines and parasiticides designed to protect against fleas, ticks and heartworm. The integration of diagnostics, such as rapid tests and instrument-based platforms, enables veterinarians to make timely, data-driven decisions at the point of care.

With operations in more than 100 countries and manufacturing facilities across North America, Europe, Latin America and the Asia-Pacific region, Zoetis serves a diverse customer base that includes veterinarians, livestock producers and distributors. The company’s global reach is supported by research centers in the United States and Europe, driving the development of novel therapies and technology platforms that meet regional and species-specific needs.

Under the leadership of President and Chief Executive Officer Kristin Peck, Zoetis continues to pursue strategic acquisitions and collaborations to expand its product portfolio and geographic footprint. The company’s commitment to advancing animal health and welfare is underpinned by ongoing investments in R&D, aimed at delivering sustainable solutions that benefit animals, their owners and the broader agricultural community.

Key Stats

• Today's Range: $148.38 to $150.00
• 50-Day Range: $145.76 to $159.19
• 52-Week Range: $139.70 to $200.33
• Volume: 303,434 shs
• Average Volume: 3.02 million shs
• Market Capitalization: $66.30 billion
• P/E Ratio: 25.77
• Dividend Yield: 1.34%
• Price Target: $200.88
• Consensus Rating: Moderate Buy

Zoetis Stock Analysis - MarketRank™

Zoetis scored higher than 97% of companies evaluated by MarketBeat, and ranked 46th out of 927 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 4.3 / 5
• Analyst Rating: Moderate Buy

Consensus Rating

Zoetis has received a consensus rating of Moderate Buy. The company's average rating score is 2.56, and is based on 5 buy ratings, 4 hold ratings, and no sell ratings.

Upside Potential

Zoetis has a consensus price target of $200.88, representing about 34.6% upside from its current price of $149.27.

Amount of Analyst Coverage

Zoetis has been the subject of 5 research reports in the past 90 days, demonstrating strong analyst interest in this stock.

Earnings and Valuation

• Score: 2.5 / 5
• Proj. Earnings Growth: 11.20%

Earnings Growth

Earnings for Zoetis are expected to grow by 11.20% in the coming year, from $6.07 to $6.75 per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of Zoetis is 25.72, which means that it is trading at a less expensive P/E ratio than the market average P/E ratio of about 279.38.

Price to Earnings Ratio vs. Sector

The P/E ratio of Zoetis is 25.72, which means that it is trading at a less expensive P/E ratio than the Medical sector average P/E ratio of about 75.69.

Price to Earnings Growth Ratio

Zoetis has a PEG Ratio of 2.44. PEG Ratios above 1 indicate that a company could be overvalued.

Price to Book Value per Share Ratio

Zoetis has a P/B Ratio of 14.12. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

Short Interest

• Score: 4.0 / 5
• Short Interest Level: Healthy

Percentage of Shares Shorted

1.49% of the float of Zoetis has been sold short.

Short Interest Ratio / Days to Cover

Zoetis has a short interest ratio ("days to cover") of 2.1, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in Zoetis has recently decreased by 4.07%, indicating that investor sentiment is improving.

Dividend

• Score: 4.2 / 5
• Dividend Strength: Strong

Dividend Yield

Zoetis pays a meaningful dividend of 1.30%, higher than the bottom 25% of all stocks that pay dividends.

Dividend Growth

Zoetis has been increasing its dividend for 14 years.

Dividend Coverage

The dividend payout ratio of Zoetis is 34.42%. This payout ratio is at a healthy, sustainable level, below 75%.

Dividend Sustainability

Based on earnings estimates, Zoetis will have a dividend payout ratio of 29.63% next year. This indicates that Zoetis will be able to sustain or increase its dividend.

Sustainability and ESG

• Score: 0.4 / 5
• Environmental Score: -4.66

Percentage of Shares Shorted

1.49% of the float of Zoetis has been sold short.

Short Interest Ratio / Days to Cover

Zoetis has a short interest ratio ("days to cover") of 2.1, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in Zoetis has recently decreased by 4.07%, indicating that investor sentiment is improving.

News and Social Media

• Score: 2.5 / 5
• News Sentiment: 1.50

News Sentiment

Zoetis has a news sentiment score of 1.50. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.84 average news sentiment score of Medical companies.

News Coverage This Week

MarketBeat has tracked 32 news articles for Zoetis this week, compared to 39 articles on an average week.

Search Interest

Only 18 people have searched for ZTS on MarketBeat in the last 30 days. This is a decrease of -14% compared to the previous 30 days.

MarketBeat Follows

Only 7 people have added Zoetis to their MarketBeat watchlist in the last 30 days. This is a decrease of -30% compared to the previous 30 days.

Company Ownership

• Score: 1.7 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, Zoetis insiders have not sold or bought any company stock.

Percentage Held by Insiders

Only 0.16% of the stock of Zoetis is held by insiders.

Percentage Held by Institutions

92.80% of the stock of Zoetis is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

ZTS Stock Analysis - Frequently Asked Questions

How have ZTS shares performed this year?

Zoetis' stock was trading at $162.93 on January 1st, 2025. Since then, ZTS shares have decreased by 8.4% and is now trading at $149.2660.

How were Zoetis' earnings last quarter?

Zoetis Inc. (NYSE:ZTS) released its quarterly earnings results on Tuesday, August, 5th. The company reported $1.76 earnings per share for the quarter, beating the consensus estimate of $1.62 by $0.14. The business's revenue was up 4.2% on a year-over-year basis.
Read the conference call transcript.

Does Zoetis have any subsidiaries?

Zoetis subsidiaries include these companies: Jorox Pty, Virtual Recall, Fish Vet Group, Performance Livestock Analytics, Ethos Diagnostic Science, ZNLabs, Phoenix Lab, and others.

Who are Zoetis' major shareholders?

Zoetis' top institutional shareholders include Vanguard Group Inc. (9.45%), State Street Corp (4.45%), Geode Capital Management LLC (2.50%) and Norges Bank (1.17%). Insiders that own company stock include Kristin C Peck, Heidi C Chen, Roxanne Lagano, Willie M Reed and Robert J Polzer.
View institutional ownership trends.

How do I buy shares of Zoetis?

Shares of ZTS stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

What other stocks do shareholders of Zoetis own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Zoetis investors own include Waste Connections (WCN), The RMR Group (RMR), iShares Micro-Cap ETF (IWC), DiamondRock Hospitality (DRH), American Water Works (AWK), AU Optronics (AUOTY) and Triple Flag Precious Metals (TFPM).

Company Calendar

• Record date for 9/3 Dividend: 7/18/2025
• Ex-Dividend for 9/3 Dividend: 7/18/2025
• Last Earnings: 8/05/2025
• Dividend Payable: 9/03/2025
• Today: 9/10/2025
• Next Earnings (Estimated): 11/03/2025
• Fiscal Year End: 12/31/2025

Industry, Sector and Symbol

• Stock Exchange: NYSE
• Sector: Medical
• Industry: MED - DRUGS
• Sub-Industry: Pharmaceuticals
• Current Symbol: NYSE:ZTS
• CIK: 1555280
• Web: www.zoetis.com
• Phone: (973) 822-7000
• Fax: 302-655-5049
• Employees: 13,800
• Year Founded: 1952

Price Target and Rating

• Average Price Target for Zoetis: $200.88
• High Price Target: $244.00
• Low Price Target: $155.00
• Potential Upside/Downside: +34.1%
• Consensus Rating: Moderate Buy
• Rating Score (0-4): 2.56
• Research Coverage: 9 Analysts

Profitability

• EPS (Trailing Twelve Months): $5.81
• Trailing P/E Ratio: 25.78
• Forward P/E Ratio: 24.68
• P/E Growth: 2.44
• Net Income: $2.49 billion
• Net Margins: 27.83%
• Pretax Margin: 35.35%
• Return on Equity: 56.90%
• Return on Assets: 19.54%

Debt

• Debt-to-Equity Ratio: 1.05
• Current Ratio: 1.76
• Quick Ratio: 1.04

Sales & Book Value

• Annual Sales: $9.39 billion
• Price / Sales: 7.07
• Cash Flow: $6.98 per share
• Price / Cash Flow: 21.46
• Book Value: $10.57 per share
• Price / Book: 14.17

Miscellaneous

• Outstanding Shares: 443,183,000
• Free Float: 442,474,000
• Market Cap: $66.39 billion
• Optionable: Optionable
• Beta: 0.88